Elite in Lung Agenesis

Toshiaki Takahashi

Okayama, JP 
Elite in Lung Agenesis
Okayama, JP 
OverviewLocationsClinical Research

Overview

Toshiaki Takahashi practices in Okayama, Japan. Mr. Takahashi is rated as an Elite expert by MediFind in the treatment of Lung Agenesis. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Endoscopy, and Osteotomy.

His clinical research consists of co-authoring 459 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Lung Agenesis.

Gender
Male

Locations

Okayama, Japan
Other Locations
Shizuoka, Japan
Tokyo, Japan
Shimonagakubo, 4118777, Japan
Hamamatsu, Japan
Hongo, Japan
Matsuyama, 7908577, Japan
Toranomon, Japan
Sennan, 5900494, Japan
Ichihara, 2900045, Japan
Kamogawa, Japan
Osaka, Japan
Toyohashi, 4418580, Japan
Tottori, Japan
Fukuoka, Japan
Toon, Japan
Kyoto, 6068502, Japan
Yokote, Japan
Akita, Japan
Hiraka, Japan
Japan
Nankoku, 7838505, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: M7824, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin
Study Phase: Phase 2

459 Total Publications

Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18.
Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Takahashi's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 23 Advanced Conditions
View All 55 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile